Hansruedi Loetscher, PhD​

Dr. Hansruedi Loetscher is a distinguished pharmaceutical research leader and Scientific Advisor to Ultimate Medicine, bringing more than 30 years of experience in neuroscience drug discovery and translational research. As former Global Head of Neuroscience Discovery at Roche, he directed programs that advanced multiple breakthrough therapeutics for Alzheimer’s disease and neurodegeneration.

At Roche, Dr. Loetscher led the discovery and preclinical development of Gantenerumab, Roche’s first-generation anti-amyloid antibody, and its brain-shuttle successor Trontinemab (RG6102). His pioneering work on TNF receptor biology, including the first cloning of the human p55 TNF receptor, laid the foundation for understanding neuroinflammatory pathways in CNS disease.

Dr. Loetscher earned his PhD in Biochemistry from ETH Zurich and completed postdoctoral research at the University of Oregon. With over 70 publications in journals such as Cell, Nature, and Neuron, and multiple patents in therapeutic antibodies and biomarkers, he provides deep scientific and strategic expertise guiding Ultimate Medicine’s Alzheimer’s and neurodegenerative programs.